Overweight and obesity linked to increased bladder cancer risk in males in meta-analysisHigher BMI and waist size linked to bladder cancer risk in men

This is a meta-analysis of 30 international cohort studies, synthesizing data from a total population of 2,533,008 participants. The review examined the association between anthropometric measures—body mass index (BMI), waist circumference, and height—and the risk of incident first primary bladder cancer. The comparator was normal weight, defined as a BMI of 18.5 to 24.9 kg/m². The primary outcome was the incidence of first primary bladder cancer.

The main results showed a clear sex-specific pattern. For males, overweight (BMI 25.0 to 29.9 kg/m²) was associated with a significantly increased risk of bladder cancer, with a hazard ratio (HR) of 1.08 (95% CI, 1.04 to 1.12). Obesity (BMI ≥30 kg/m²) in males was also associated with an increased risk, with an HR of 1.16 (95% CI, 1.10 to 1.22). In contrast, for females, neither overweight (HR 1.02, 95% CI 0.95 to 1.09) nor obesity (HR 1.04, 95% CI 0.95 to 1.14) showed a statistically significant increase in bladder cancer risk.

Further analyses per incremental units of BMI and waist circumference reinforced this sex difference. In males, each 5 kg/m² increment in BMI was associated with a 7% increased risk of bladder cancer (HR 1.07, 95% CI 1.05 to 1.09). Each 10 cm increase in waist circumference in males was associated with a 6% increased risk (HR 1.06, 95% CI 1.03 to 1.08). For females, neither a 5 kg/m² increment in BMI (HR 1.00, 95% CI 0.97 to 1.04) nor a 10 cm increase in waist circumference (HR 1.01, 95% CI 0.97 to 1.04) was associated with a significant change in risk.

The review did not report data on key secondary outcomes, such as bladder cancer mortality or stage-specific incidence. Safety and tolerability data related to the exposures (BMI, waist circumference) were not reported, as this was a meta-analysis of observational studies on risk factors, not a therapeutic intervention. The follow-up duration for the included cohort studies was not reported.

These results can be compared to prior landmark studies and reviews on obesity and cancer risk. The observed associations for males are consistent with a broader body of evidence linking excess adiposity to various cancers, though the magnitude of the HRs (1.08 to 1.16) indicates a modest relative risk increase. The lack of a significant association in females is a key finding that may align with some previous studies showing sex-specific patterns in obesity-related cancer risks, though this is not universally reported.

Key methodological limitations are inherent to the meta-analysis of observational studies. The review does not detail specific limitations, but such analyses are subject to confounding by unmeasured factors (e.g., smoking, occupational exposures), heterogeneity in BMI measurement across studies, and potential publication bias. The causality note explicitly states these are associations, not causal relationships.

The clinical implications are primarily public health-oriented. The practice relevance statement suggests that interventions to prevent overweight and obesity, alongside smoking cessation and reduced exposure to bladder carcinogens, could help reduce bladder cancer incidence worldwide. For individual patient care, these findings support discussing weight management as part of a holistic risk reduction conversation for male patients, particularly those with other risk factors.

Several questions remain unanswered. The mechanisms underlying the sex-specific differences are not elucidated. The impact of weight loss or changes in anthropometric measures over time on bladder cancer risk was not addressed. The role of specific adipose tissue depots (e.g., visceral vs. subcutaneous fat) beyond waist circumference is not explored. Future research should focus on these gaps to better inform targeted prevention strategies.